Sotorasib for advanced non-small cell lung cancer

Bookmark and Share
Published: 6 Nov 2020
Views: 1556
Prof Fabrice Barlesi - Gustave Roussy, Villejuif, France

Prof Fabrice Barlesi speaks to ecancer about the ESMO 2020 virtual congress concerning sotorasib for non-small cell lung cancer (NSCLC).

The patients involved had solid tumours harbouring KRAS p.G12C mutations.

Prof Barlesi explains the adverse events, efficacy, and future prospects for the drug.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Sotorasib for advanced non-small cell lung cancer

Prof Fabrice Barlesi - Gustave Roussy, Villejuif, France

Hi everyone, I’m Fabrice Barlesi from the Gustave Roussy cancer campus in Paris and ex-Marseilles University. I would like to summarise the data presented during ESMO 2020 regarding the AMG-510, sotorasib, which is a specific KRAS G12C inhibitor. During the meeting the updated results of the phase I study were presented. As you know, this study was dedicated to advanced non-small cell lung cancer patients with a G12C mutation, KRAS mutation, with different levels of dosage for the drug and a summary of the extension phase.

The drug was quite well tolerated. When we look at the treatment related adverse events, 60% of the patients presented with at least treatment related adverse events with 18.6% presenting with a grade 3 or more treatment related adverse event.

Very importantly, the efficacy was updated during this presentation. The overall response rate in this heavily pre-treated patient population was 35.3% which has to be put in line with the expected 12-15% response rate with docetaxel which was the standard of care up until now. Then these updated results make sotorasib a potential new future standard of care in this patient population and we look to the advance and the results of the phase III ongoing trial.